Liquid biopsy startup AOA Dx has collected $17 million in a Series B raise to support the development of its diagnostic test for ovarian cancer as well as the platform on which it is based.
The company’s diagnostic platform, GlycoLocate, is designed to detect cell signaling molecules called gangliosides in the blood. Elevated levels are often seen in cancer patients.
In January, AOA Dx started its prospective study OVERT to investigate its first diagnostic test, AKRIVIS GD, for ovarian cancer. The trial is recruiting across 20 US sites such as hospitals, gynecology and oncology clinics, CEO Oriana Papin-Zoghb told Endpoints News.
The Series B will fund the trial, assist the company in building new lab facilities in Denver, CO, and further develop GlycoLocate. AOA Dx currently has about 18 employees, with Papin-Zoghbi noting it is looking to grow.
Investors in the Series…
Click here to view original post
